News and Insights
The latest news and insights from Genoa Healthcare.
- Behavioral Health
- Clinical Insights
- Treatment
August 2023 drug trend report
Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Uzedy Abilify Asimtuffii Brixadi Generic...
- Aug 2nd, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Frequently asked questions: naloxone (Narcan®)
Narcan® information and sources were taken from www.narcan.com. 1. FDA Approves First Over-the-Counter Naloxone Nasal Spray. 3/29/2023. FDA Approves First Over-the-Counter Naloxone Nasal Spray | FDA
- Mar 29th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Frequently asked questions: buprenorphine-containing products
Information and sources on buprenorphine-containing products were taken from www.sublocade.com and www.suboxone.com.
- Mar 6th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
What’s on the horizon: four emerging trends in the medication-assisted treatment space
1X-Waiver no longer need to treat opioid use disorder. (2023, January 13). ACEP. 2. Sublocade. 3.BMC launces app to help providers treat patients with opioid use disorder. (2021, March 22)....
- Mar 6th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Webinar: Medication-assisted Treatment: Trends and Outcomes
For consumers living with opioid use disorder (OUD), medication-assisted treatment (MAT) has become the gold standard of treatment. In a new webinar, Genoa Healthcare Director of Operations Megan Garrity, PharmD,...
- Dec 20th, 2022
- Behavioral Health
- Clinical Insights
- Treatment
New medication options in behavioral health
FDA Approves 14 New Medications The FDA has approved 14 new medication and treatment options for the behavioral health space to date in 2022. The new medication and treatment options...
- Jun 24th, 2022
- Behavioral Health
- Clinical Insights
- Treatment
Webinar: Long-Acting Injectable Antipsychotics in Practice
Treating Schizophrenia Long-acting injectable (LAI) antipsychotic formulations are being considered more often in the treatment of schizophrenia to promote medication adherence. Genoa Healthcare recently hosted a webinar providing an update...
- Dec 9th, 2021
- Behavioral Health
- Clinical Insights
- Treatment
Webinar: New Medication Options in Behavioral Health
Behavioral Health Drug Updates This year the Federal Drug Administration’s Center for Drug Evaluation and Research (CDER) approved a number of new drug therapies to treat behavioral health conditions, including...
- Oct 8th, 2021
- Behavioral Health
- Clinical Insights
- Treatment
Webinar: What Providers Need to Know: New Medication Options in Behavioral Health
Behavioral Drug Approvals in 2020 The FDA’s Center for Drug Evaluation and Research approved 53 new drugs in 2020 alone, including several novel treatments for schizophrenia and other behavioral health...
- Jul 6th, 2021
- Behavioral Health
- Clinical Insights
- Treatment
Webinar: Substance Use Disorder and Medication Assisted Therapies
A Rise in Drug Overdoses Deaths from drug overdoses, which have climbed steadily over the past 20 years, rose sharply during the COVID-19 pandemic. This “epidemic within the pandemic” underscored...
- Jun 30th, 2021